Denali therapeutics announces initiation of phase 1b study of eif2b activator dnl343 in als

— investigational eif2b activator approach has potential to be a first-in-class treatment for als — — investigational eif2b activator approach has potential to be a first-in-class treatment for als —

DNLI Ratings Summary

DNLI Quant Ranking